Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.

Journal Article (Journal Article)

Obesity emerged as a risk factor for morbidity and mortality related to 2009 pandemic influenza A (H1N1) infection. However, few studies examine the immune responses to H1N1 vaccine among children and adults of various body mass indices (BMI). Pooling data from 3 trials of unadjuvanted split-virus H1N1 A/California/07/2009 influenza vaccines, we analyzed serologic responses of participants stratified by BMI grouping. A single vaccine dose produced higher hemagglutination inhibition antibody titers at day 21 in obese compared to nonobese adults, but there were no significant differences in responses to H1N1 vaccine among children or adults of various BMI following 2 doses.

Full Text

Duke Authors

Cited Authors

  • Callahan, ST; Wolff, M; Hill, HR; Edwards, KM; NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group,

Published Date

  • October 15, 2014

Published In

Volume / Issue

  • 210 / 8

Start / End Page

  • 1270 - 1274

PubMed ID

  • 24795475

Pubmed Central ID

  • PMC4271072

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiu245


  • eng

Conference Location

  • United States